A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...
In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...
Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer. Discover why early detection makes treatment more effective and far less ...
In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of anticoagulants published by Wiley online in CANCER, investigators found ...
News-Medical.Net on MSN
Taking anticoagulants alongside prostate cancer drugs does not increase bleeding risk
In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...
Scientists have reported results from an early-stage trial of an immunotherapy drug called VIR-5500. The drug offers new hope for men with advanced prostate cancer who have stopped responding to other ...
News-Medical.Net on MSN
FOXJ1 gene may drive resistance to taxane chemotherapy in advanced prostate cancer
A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...
Adelaide newsreader Will McDonald has managed his aggressive stage 4 prostate cancer for six years now, although he knows the intensive drug regime he is on, while doing the trick for now, won’t last ...
Oxybutynin significantly reduced hot flash frequency and severity compared with placebo among men with prostate cancer ...
In a second EU approval today, Johnson & Johnson got a green light for Akeega (niraparib and abiraterone acetate) for the ...
Stockhead on MSN
Health Check: Telix jumps first hurdle with its advanced prostate cancer therapy trial
In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ... Read More The post Health Check: Telix jumps first hurdle with its ...
Thirty-six progressive mCRPC patients received TLX591-Tx across three cohorts (enzalutamide, abiraterone, or docetaxel sequence), and all completed two planned doses without emergent, unexpected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results